Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2019 Earnings Conference Call - Final Transcript
Nov 14, 2019 • 08:00 am ET
Good day. Welcome to the BrainStorm Cell Therapeutics Third Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation.
As a reminder, this call is recorded. I would now like to introduce your host, Sean Leous from ICR Westwicke. You may begin, sir.
Thank you for joining the BrainStorm Cell Therapeutics third quarter financial results conference call. Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics, Inc. and its potential future business operations and performance statements regarding the market potential for treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2019 and beyond, the safety and clinical effectiveness of our NurOwn technology platform, our clinical trials of NurOwn and related clinical development programs, and our ability to develop strategic collaborations and partnerships to support business planning efforts.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings. Our results may differ material from those projected here on today's call. We undertake no obligation to publicly update any forward-looking statements. Joining me on the call today will be Chaim Lebovits, President and CEO of BrainStorm, Dr. Ralph Kern, Chief Operating Officer, Chief Medical Officer, and Preetam Shah, our Chief Financial Officer. We will be available to answer your questions during the Q&A session.
Thank you, Sean. Good morning and good afternoon to everyone on the third quarter earnings call. Let me begin by thanking everyone for participating in today's call, such an early time and for all those that send their questions prior to our call. We will address many of your pre-submitted questions in the opening remarks and we look forward to addressing any additional questions or comments you may have in the Q&A session.
On behalf of the entire BrainStorm management team, I want to express our thanks for the ongoing and continued support of so many. I must thank and acknowledge, first in all, the patients, their families, caregivers and all those who are helping us advance the Phase 3 ALS trial and the Phase 2 progressive MS trial. Also I want to thank the team here at BrainStorm, who fully devoted themselves to advance best-in-class and potentially life altering therapies. Finally, I want to thank our shareholders for their continued ongoing support and our collective journey towards FDA approval. During this quarter, we achieved major milestones. Firstly, we fully enrolled our Phase 3 ALS clinical trial, which we announced on October 11.
We began enrollment in October of 2017, even though many were skeptical and two years later we enrolled all 200 patients. Starting to evaluate the repeated intrathecal administration of NurOwn cellular therapeutics. The medical statistics, clinical centers of excellence, University of California, Irvine, Cedars-Sinai Medical